Elastic band resistance training versus whole-body electrical muscle stimulation for people with cancer.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study compares a 12-week supervised elastic band resistance program to several whole-body electromyostimulation (WB-EMS) exercise regimens, including a sham WB-EMS and a free WB-EMS format. Participants are adults with solid or hematologic malignancies who are receiving curative or palliative anti-cancer therapy and have ECOG performance status 0–2. Primary outcomes include muscle strength and body composition (muscle mass), with additional measures of cardiorespiratory fitness, inflammatory markers, and patient-reported outcomes such as quality of life, fatigue, and performance status. Intervention sessions and outcome assessments take place at the University of Erlangen-Nürnberg Hector-Center over the 12-week period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* malignant disease (solid or hematological cancer): head and neck cancer, colorectal carcinoma, small intestinal cancer, gastric cancer, oesophageal cancer, pancreas carcinoma, liver cell carcinoma, cholangiocarcinoma, lung cancer, breast cancer, cervix cancer, ovarian cancer, prostate cancer, renal cell carcinoma, malignant melanoma, patients with leukaemia and malignant lymphomas or Graft-versus-Host-Disease after bone marrow transplantation
* ongoing or planned curative or palliative anti-cancer therapy
* ECOG-Status 0-2

Exclusion Criteria:

* simultaneous participation in other nutritional or exercise intervention Trials
* bone metastases with high fracture risk
* cardiovascular disease
* use of anabolic medications
* epilepsy
* severe neurological or rheumatic diseases
* skin lesions in the area of electrodes
* energy active metals in body
* pregnancy
* acute vein thrombosis

Where it's running

• Department of Medicine 1, Hector-Center for Nutrition, Exercise and Sports
  Erlangen, Germany Recruiting

Study contacts

• Principal investigator: Dejan Reljic, Dr. — University Erlangen Nuremberg Medical School
• Study coordinator: Hans Joachim Herrmann, Dr.
• Email: hans.herrmann@uk-erlangen.de
• Phone: +49 9131 8545218

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of QLS2319 in healthy adults and cancer cachexia

  This study tests QLS2319 in healthy adults and people with cancer cachexia to see if it is safe, tolerated, and how it behaves in the body, with a look at early signs of benefit.

  Recruiting Phase 1/2 Qilu Pharmaceutical Co., Ltd. · Hefei, Anhui and 1 other locations · NCT07735104

• Omega-3 supplements plus progressive resistance training for cancer-related muscle loss

  This study tests whether fish oil and a structured resistance-training program can help improve muscle status in adults with various cancers who are receiving treatment.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT07643558

• First-in-human testing of FID-022 in solid tumor patients

  This project will test an AI tool to spot early cancer-related weight loss and see if diet and exercise support are acceptable for people with newly diagnosed pancreatic cancer.

  Recruiting H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07249775

• Single-dose GB18 injections in healthy adults (dose-escalation)

  This trial will test single subcutaneous doses of GB18 versus placebo in healthy adults to see if the drug is safe, how it behaves in the body, how it affects the circulating protein GDF15, and whether it triggers immune responses.

  Recruiting Phase 1 Kexing Biopharm Co., Ltd. · Beijing, Beijing Municipality · NCT07237464

• How young adults' thigh muscles change after five days of strict bedrest

  We will test whether five days of strict bedrest changes muscle size, strength, fatigue resistance, and whole-body insulin sensitivity in healthy 18–30-year-olds.

  Recruiting Queen's University · Kingston, Ontario · NCT07178353

• Psilocybin-assisted psychotherapy for anxiety after a cancer diagnosis

  This study will test whether psilocybin-assisted psychotherapy using NPX-5 (25 mg or 10 mg versus a low 1 mg dose) helps adults who have anxiety from adjusting to a cancer diagnosis.

  Recruiting at 5 sites Phase 2 Psyence Australia Pty Ltd · Abbotsford, Victoria and 4 other locations · NCT07072728

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.